COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,100 Articles (22,658 medRxiv, 8,442 bioRxiv)

Most recent first Previous |  Page 129: Articles 1281-1290  | Next

Inconsistent Rebound of Invasive Pneumococcal Disease in Connecticut following the Initial Phase of the SARS-CoV-2 Pandemic
Perniciaro, S. R., Weinberger, D. M.
10.1101/2024.11.02.24316649 — Posted: 2024-11-04
Assessing Neuropsychiatric Symptoms in Long COVID: A Retrospective Cohort Study from a South Texas Long COVID Clinic
Wells, A. M., Rolin, S., Robles-Ramamurthy, B. F., Gibson-Lopez, G., Goros, M., Gelfond, J. A., Gelfond, S., Balfanz, P., Deuter, M., McGeary, D., Verduzco Gutierrez, M.
10.1101/2024.11.03.24316669 — Posted: 2024-11-04
Lineage Detector: Efficient Tool for Detecting New SARS-Cov-2 Lineages
Zou, X.
10.1101/2024.11.01.621557 — Posted: 2024-11-04
COVID-19 disease and economic burden in adults in six Latin American Countries before nationwide vaccination program: Ministry of Health databases assessment and systematic literature review
Espinola, N., Loudet, C., Luxardo, R., Moreno, C., Kyaw, M., Spinardi, J., Mendoza, C. F., Carolina, C., Dantas, A. C., Abalos, M. G., Ballivian, J., Navarro, E., Bardach, A.
10.1101/2024.10.31.24316541 — Posted: 2024-11-02
Pulmonary barotrauma in COVID-19 patients: Experience from a tertiary university hospital
Chai, J. H., Masdar, A., Mohamad Yusof, A., Wan Mat, W. R.
10.1101/2024.10.31.24316477 — Posted: 2024-11-02
Immunogenicity and safety of a monovalent Omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine in previously unvaccinated, SARS-CoV-2 seropositive participants: primary day-28 analysis of a phase 2/3 open-label study
Alves, K., Kouassi, A., Plested, J. S., Kalkeri, R., Smith, K., Kaba, M., Nelson, J., Zhu, M., Cloney-Clark, S., Cai, Z., Mallory, R., Noriega, F.
10.1101/2024.10.25.24316129 — Posted: 2024-11-01
Spatial Patterns of COVID-19 Mortality: Examining Socioeconomic Determinants in U.S. Counties Using Cluster Analysis
Wardrup, R. R.
10.1101/2024.10.30.24316443 — Posted: 2024-11-01
RGFSAMNet: An interpretable COVID-19 detection and classification by using the deep residual network with global feature fusion and attention mechanism
Karim, S. M. R. U., Bala, D., Rasul, R. A., Goggins, S.
10.1101/2024.10.30.24316451 — Posted: 2024-11-01
Quality of vaccination-induced T cell responses is conveyed by polyclonality and high, but not maximum, antigen receptor avidity
Kocher, K., Drost, F., Tesfaye, A. M., Moosmann, C., Schuelein, C., Grotz, M., D'Ippolito, E., Graw, F., Spriewald, B., Busch, D. H., Bogdan, C., Tenbusch, M., Schubert, B., Schober, K.
10.1101/2024.10.30.620795 — Posted: 2024-10-31
Antigenic imprinting dominates humoral responses to new variants of SARS-CoV-2 in a hamster model of COVID-19
Degryse, J., Maas, E., Lassauniere, R., Geerts, K., Kumpanenko, Y., Weynand, B., Maes, P., Neyts, J., Thibaut, H. J., Alpizar, Y. A., Dallmeier, K.
10.1101/2024.10.30.621174 — Posted: 2024-10-31

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).